Valuation: Nanobiotix

Market Cap 1.7B 1.96B 1.58B 1.45B 2.73B 187B 2.78B 18.59B 7.3B 93.58B 7.37B 7.21B 309B P/E 2026 *
-81.5x
P/E 2027 * -141x
Enterprise Value 1.74B 2.01B 1.63B 1.49B 2.81B 192B 2.85B 19.1B 7.5B 96.12B 7.57B 7.4B 318B EV / Sales 2026 *
45.8x
EV / Sales 2027 * 41.4x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week-0.77%
Current month-0.77%
1 month+1.09%
3 months-6.64%
6 months+86.51%
Current year+71.59%
1 week 31.94
Extreme 31.94
35.52
1 month 30.5
Extreme 30.5
37.46
Current year 16.66
Extreme 16.66
47.66
1 year 6.21
Extreme 6.21
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap.
7/17/26 Buy

Chairman

598 0.0012%
7/17/26 Buy

Chairman

598 0.0012%
7/16/26 Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-0.77%+454.89%+358.98% 1.94B
+0.99%+1.78%+4.07%+16.73% 48.7B
+3.71%+9.40%+486.98%+592.14% 42.05B
+2.70%+1.57%+33.39%+8.85% 38.26B
+5.60%+10.21%+16.76%+85.72% 37.5B
+2.21%+6.75%+21.31%+53.37% 31.44B
+2.23%+4.71% - - 16.47B
+0.97%+2.35%+37.75%+126.84% 16.33B
-0.11%+2.41%+6.24%+18.87% 13.98B
+0.75%+15.04%+78.59%+30.30% 12.68B
Average +1.98%+4.99%+126.67%+143.53% 25.93B
Weighted average by Cap. +2.50%+4.99%+106.38%+141.48%

Financials

2026 *2027 *
Net sales 38.06M 44M 35.54M 32.61M 61.33M 4.19B 62.3M 417M 164M 2.1B 165M 162M 6.94B 42.83M 49.51M 39.99M 36.69M 69.01M 4.71B 70.1M 469M 184M 2.36B 186M 182M 7.81B
Net income -12.18M -14.08M -11.37M -10.43M -19.62M -1.34B -19.93M -133M -52.36M -671M -52.86M -51.7M -2.22B -52.44K -60.62K -48.97K -44.92K -84.5K -5.77M -85.84K -575K -226K -2.89M -228K -223K -9.56M
Net Debt 46M 53.18M 42.96M 39.41M 74.12M 5.06B 75.3M 504M 198M 2.54B 200M 195M 8.39B 76.4M 88.33M 71.35M 65.45M 123M 8.41B 125M 837M 329M 4.21B 332M 324M 13.93B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-08-07 €33.46 +0.78% 121,944
26-08-06 €33.20 -2.30% 52,660
26-08-05 €33.98 -0.93% 129,866
26-08-04 €34.30 +1.48% 53,374
26-08-03 €33.80 +0.24% 146,938
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.46EUR
Average target price
52.20EUR
Spread / Average Target
+56.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock